Risedronate induced BOOP complicated with sarcoidosis [3]

Thorax

Volumn 60, Issue 7, 2005, Pages 613-614

  Arai, T ^a   Inoue, Y ^a   Hayashi, S ^a   Yamamoto, S ^a   Sakatani, M ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MENATETRENONE; NEUROTROPIN; PRAVASTATIN; PREDNISOLONE; RISEDRONIC ACID; SAIREI TO;

AGED; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CASE REPORT; FEMALE; HUMAN; LETTER; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; SARCOIDOSIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AGED; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CALCIUM CHANNEL BLOCKERS; ETIDRONIC ACID; FEMALE; HUMANS; MUSCULAR DISEASES; OSTEOPOROSIS; SARCOIDOSIS; SARCOIDOSIS, PULMONARY;

EID: 22044434869     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.043893     Document Type: Letter

References (5)

1. Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001;68:945-51.
2. Rolla G, Bucca C, Brussino L. Bisphosphonate- induced bronchoconstriction in aspirin-sensitive asthma. Lancet 1994;343:426-7.
3. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-70.
4. Thiebaud D, Sauly A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61:386-92.
5. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220-4.